Bensultap is a selective serotonin reuptake inhibitor (SSRI) that is currently under investigation for the treatment of major depressive disorder (MDD). Its mechanism of action involves inhibiting the reuptake of serotonin in the synapse, which increases serotonin levels in the brain. Bensultap is being studied because it has shown promise in preclinical trials as a potential treatment for MDD, particularly in patients who have not responded well to other SSRI medications. However, it is still in the early stages of clinical development, and its safety and efficacy in humans have yet to be fully established. The synthesis of bensultap involves a multi-step process that starts with the preparation of a key intermediate, followed by a series of reactions to introduce the desired functional groups and ultimately form the final product. The exact details of the synthesis process are proprietary information, and it is not publicly available.'
| ID Source | ID |
|---|---|
| PubMed CID | 87176 |
| CHEMBL ID | 2270410 |
| CHEBI ID | 39188 |
| SCHEMBL ID | 20437 |
| MeSH ID | M0152066 |
| Synonym |
|---|
| AC-12668 |
| zz-doricida insecticide |
| brn 2228033 |
| ruban |
| victenon |
| zz-doricida |
| benzenesulfonic acid, thio-, s,s'-(2-(dimethylamino)trimethylene) ester |
| ti-1671 |
| bensultap [bsi:iso] |
| ti-78 |
| bancol |
| s,s'-(2-(dimethylamino)-1,3-propanediyl) dibenzenesulfothioate |
| NCGC00160441-01 |
| thiobenzenesulfonic acid s,s'-(2-(dimethylamino)trimethylene) ester |
| 17606-31-4 |
| s,s'-2-dimethylaminotrimethylene di(benzenethiosulphonate) |
| bensultap |
| s,s'-(2-(dimethylamino)trimethylene)bis(benzenethiosulfonate) |
| s,s'-(2-(dimethylamino)-1,3-propanediyl)dibenzenesulfothioate |
| s,s'-2-dimethylaminotrimethylene di(benzenethiosulfonate) |
| s,s'-[2-(dimethylamino)propane-1,3-diyl] dibenzenesulfonothioate |
| CHEBI:39188 , |
| nereistoxin dibenzenesulfonate |
| AKOS000526037 |
| inchi=1/c17h21no4s4/c1-18(2)15(13-23-25(19,20)16-9-5-3-6-10-16)14-24-26(21,22)17-11-7-4-8-12-17/h3-12,15h,13-14h2,1-2h3 |
| yfxppskymbtnav-uhfffaoysa- |
| n,n-dimethyl-1,3-bis(phenylsulfonylsulfanyl)propan-2-amine |
| 1,3-bis(benzenesulfonylsulfanyl)-n,n-dimethylpropan-2-amine |
| C18563 |
| benzenesulfonothioic acid, s,s'-(2-(dimethylamino)-1,3-propanediyl) ester |
| unii-145q2e77pj |
| 145q2e77pj , |
| CCG-2280 |
| benzenesulfonothioic acid, s,s'-[2-(dimethylamino)-1,3-propanediyl] ester |
| CHEMBL2270410 |
| s,s'-2-dimethylaminotrimethylene di(benzenethiosulfonate |
| bensultap [iso] |
| s,s'-(2-(dimethylamino)-1,3-propanediyl) di(benzenesulfonothioate) |
| AB01334199-02 |
| SCHEMBL20437 |
| 1,3-bis(benzenesulfonylthio)-2-(n,n-dimethylamino)propane |
| DTXSID6058001 |
| benzenesulfonothioic acid, s1,s1'-[2-(dimethylamino)-1,3-propanediyl] ester |
| bensultap, pestanal(r), analytical standard |
| J-011160 |
| Z56756139 |
| s,s'-2-(dimethylamino)propane-1,3-diyl dibenzenesulfonothioate |
| bensultap 100 microg/ml in acetonitrile |
| Q818194 |
| bancol; ruban; victenon; zz-doricida |
| NCGC00160441-02 |
| Class | Description |
|---|---|
| nereistoxin analogue insecticide | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (28.10) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||